MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
Open Access
- 1 February 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 9, 113-126
Abstract
Objective: Lenvatinib is a first-line multikinase inhibitor for advanced hepatocellular carcinoma (HCC), but resistance to the drug remains a major hurdle for its long-term anti-cancer activity. This resistance is thought to be due to overexpression of c-Met. This study aims to identify potential upstream microRNAs (miRNAs) that regulate c-Met, investigate the underlying mechanisms, and seek potential strategies that may reverse such resistance. Methods: Lenvatinib-resistant HCC (LR-HCC) cells were established from human HCC Huh7 and SMMC-7721 cells. Assays of cell proliferation, cell cycle distribution, apoptosis, RT-qPCR, Western blot analysis and immunohistochemistry were employed. Potential miRNAs were screened by miRNA-target prediction tools and their regulatory effects were evaluated by luciferase reporter assays. Xenograft tumor models were used to evaluate the therapeutic effects. Results: LR-HCC cells were refractory to lenvatinib-induced growth inhibition and apoptosis in vitro and in vivo. Sustained exposure of cells to lenvatinib resulted in increased expression and phosphorylation of c-Met, and c-Met inhibition enhanced the effects of lenvatinib in suppressing LR-HCC cells. Among eleven miRNA candidates, miR-128-3p displayed the most vigorous activity to negatively regulate c-Met and was downregulated in LR-HCC cells. MiR-128-3p mimics inhibited proliferation and induced apoptosis of LR-HCC cells, and enhanced the effects of lenvatinib in cell culture and animal models. MiR-128-3p and c-Met participate in the mechanisms underlying lenvatinib resistance through regulating Akt that mediates the apoptotic pathway and ERK (extracellular-signal-regulated kinase) modulating cell cycle progression. Conclusion: The present results indicate that the miR-128-3p/c-Met axis may be potential therapeutic targets for circumventing lenvatinib resistance in HCC and warrant further investigation.Keywords
This publication has 39 references indexed in Scilit:
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2016
- Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cellsCancer Science, 2016
- Lenvatinib: A Potential Breakthrough in Advanced Hepatocellular Carcinoma?Future Oncology, 2016
- Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical CarcinomaCancer Research, 2015
- miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patientsOncology Reports, 2015
- Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular CarcinomaMolecular Cancer Therapeutics, 2014
- Met as a therapeutic target in HCC: Facts and hopesJournal of Hepatology, 2014
- MicroRNAs in CancerAnnual Review of Pathology: Mechanisms of Disease, 2014
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- MET: a promising anticancer therapeutic targetNature Reviews Clinical Oncology, 2012